Heska (NASDAQ:HSKA) Research Coverage Started at Guggenheim

Guggenheim started coverage on shares of Heska (NASDAQ:HSKA) in a research report report published on Thursday, May 23rd, BenzingaRatingsTable reports. The firm issued a neutral rating on the medical research company’s stock.

A number of other equities analysts have also issued reports on HSKA. BidaskClub raised shares of Heska from a sell rating to a hold rating in a research report on Wednesday, March 27th. Zacks Investment Research downgraded shares of Heska from a buy rating to a hold rating in a research note on Friday, February 8th. Benchmark downgraded shares of Heska from a buy rating to a hold rating in a research report on Wednesday, February 27th. Sidoti downgraded shares of Heska from a buy rating to a neutral rating in a research report on Tuesday, February 26th. Finally, B. Riley reduced their price target on shares of Heska from $93.00 to $87.00 and set a neutral rating on the stock in a research report on Wednesday, February 27th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. Heska currently has a consensus rating of Hold and a consensus price target of $109.00.

NASDAQ HSKA traded up $1.58 during trading on Thursday, reaching $79.48. The company’s stock had a trading volume of 72,700 shares, compared to its average volume of 82,518. The company has a quick ratio of 1.45, a current ratio of 2.66 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $601.99 million, a PE ratio of 55.97 and a beta of 0.84. Heska has a 1-year low of $68.74 and a 1-year high of $114.50.

Heska (NASDAQ:HSKA) last posted its earnings results on Tuesday, May 7th. The medical research company reported $0.10 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.19. Heska had a net margin of 3.63% and a return on equity of 8.36%. The firm had revenue of $29.51 million during the quarter, compared to analysts’ expectations of $35.21 million. As a group, equities analysts anticipate that Heska will post 0.03 EPS for the current year.

In other news, Director Scott Humphrey acquired 1,000 shares of the firm’s stock in a transaction dated Thursday, May 30th. The stock was purchased at an average price of $73.79 per share, for a total transaction of $73,790.00. Following the completion of the acquisition, the director now directly owns 3,062 shares in the company, valued at approximately $225,944.98. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 14.00% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Manchester Capital Management LLC increased its position in Heska by 128.6% during the 1st quarter. Manchester Capital Management LLC now owns 400 shares of the medical research company’s stock valued at $34,000 after buying an additional 225 shares in the last quarter. We Are One Seven LLC acquired a new position in shares of Heska in the 4th quarter valued at $86,000. LS Investment Advisors LLC increased its position in shares of Heska by 30.1% in the 4th quarter. LS Investment Advisors LLC now owns 1,133 shares of the medical research company’s stock valued at $98,000 after acquiring an additional 262 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of Heska by 47,400.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,425 shares of the medical research company’s stock valued at $121,000 after acquiring an additional 1,422 shares during the period. Finally, Bank of Montreal Can increased its position in shares of Heska by 11.7% in the 4th quarter. Bank of Montreal Can now owns 1,876 shares of the medical research company’s stock valued at $162,000 after acquiring an additional 196 shares during the period. Hedge funds and other institutional investors own 88.96% of the company’s stock.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Further Reading: Google Finance Portfolio Tips and Tricks

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.